Article Text

Download PDFPDF

Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India
  1. Patrick K Moonan1,
  2. Sreenivas A Nair2,
  3. Reshu Agarwal3,
  4. Vineet K Chadha4,
  5. Puneet K Dewan5,
  6. Umesh D Gupta6,
  7. Christine S Ho3,
  8. Timothy H Holtz3,
  9. Ajay M Kumar7,
  10. Nishant Kumar8,
  11. Prahlad Kumar9,
  12. Susan A Maloney1,
  13. Sundari R Mase10,
  14. John E Oeltmann1,
  15. C N Paramasivan11,
  16. Malik M Parmar12,
  17. Kiran K Rade12,
  18. Ranjani Ramachandran12,
  19. Raghuram Rao8,
  20. Virendra S Salhorta8,
  21. Rohit Sarin13,
  22. Sanjay Sarin11,
  23. Kuldeep S Sachdeva8,
  24. Sriram Selvaraju14,
  25. Rupak Singla15,
  26. Diya Surie1,
  27. Jamhoih Tonsing16,
  28. Srikanth P Tripathy17,
  29. Sunil D Khaparde8
  1. 1 Global Tuberculosis Branch, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  2. 2 Stop TB Partnership, Geneva, Switzerland
  3. 3 CDC India Country Office, U.S. Centers for Disease Control and Prevention, New Delhi, India
  4. 4 Department of Epidemiology and Research, National Tuberculosis Institute, Bangalore, India
  5. 5 Global Health, Bill and Melinda Gates Foundation, Seattle, USA
  6. 6 National JALMA Institute for Leprosy and other Mycobacterial Diseases, Agra, India
  7. 7 Department of Research, International Union Against Tuberculosis and Lung Disease, Paris, France
  8. 8 Revised National Tuberculosis Control Programme, India Ministry of Health and Family Welfare, New Delhi, India
  9. 9 National Tuberculosis Institute, Bangalore, India
  10. 10 WHO India Country Office, World Health Organization, New Delhi, India
  11. 11 India Country Office, Foundation for Innovative New Diagnostics, New Delhi, India
  12. 12 India Country Office, World Health Organization, New Delhi, India
  13. 13 National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
  14. 14 Department of Epidemiology, National Institute for Research in Tuberculosis, Chennai, India
  15. 15 Department of Tuberculosis and Respiratory Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
  16. 16 South-east Asia Office, International Union Against Tuberculosis and Lung Disease, New Delhi, India
  17. 17 National Institute for Research in Tuberculosis, Chennai, India
  1. Correspondence to Dr Patrick K Moonan; pmoonan{at}cdc.gov

Footnotes

  • PKM and SAN contributed equally.

  • Handling editor Alberto L Garcia-Basteiro

  • Contributors PKM and SAN conceived, designed and drafted the initial manuscript. PKM, VKC, JEO acquired and analysed the data. RA, CH, THH and DS provided technical support to interpreting the results. RA, VKC, PD, UDG, CH, THH, AK, NK, PK, SAM, SRM, JEO, CNP, MMP, KKR, RR, RR, VSS, RS, SS, KSS, SS, RS, DS, JT, SPT and SDK revised the initial draft and provided critically important intellectual content. PKM and SAN integrated all feedback and investigated and resolved any questions from internal and required clearance at CDC and WHO prior to publication. SDK provided overall leadership and oversight. All authors attest to the accuracy and integrity of final version.

  • Funding This study was funded in part by U.S. President’s Emergency Plan for AIDS Relief.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Unless otherwised stated, all data presented are in the public domain and freely avaialble for use.

View Full Text

Statistics from Altmetric.com

Footnotes

  • PKM and SAN contributed equally.

  • Handling editor Alberto L Garcia-Basteiro

  • Contributors PKM and SAN conceived, designed and drafted the initial manuscript. PKM, VKC, JEO acquired and analysed the data. RA, CH, THH and DS provided technical support to interpreting the results. RA, VKC, PD, UDG, CH, THH, AK, NK, PK, SAM, SRM, JEO, CNP, MMP, KKR, RR, RR, VSS, RS, SS, KSS, SS, RS, DS, JT, SPT and SDK revised the initial draft and provided critically important intellectual content. PKM and SAN integrated all feedback and investigated and resolved any questions from internal and required clearance at CDC and WHO prior to publication. SDK provided overall leadership and oversight. All authors attest to the accuracy and integrity of final version.

  • Funding This study was funded in part by U.S. President’s Emergency Plan for AIDS Relief.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Unless otherwised stated, all data presented are in the public domain and freely avaialble for use.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.